ALKEM’s domestic business is its key strength. With strong market positions in anti-infective, gastrointestinal and pain segments, Alkem is a leader in acute therapy segments.
In recent years, ALKEM has entered chronic segments such as cardiology, anti-diabetics and dermatology, and has deployed a sales force of ~3000 in these segments.
Pan-India presence, strong distribution network (>7,000 stockists), doctor relationships and tier III/IV/rural reach should aid ALKEM in increasing share in chronic therapies
ALKEM has built a decent platform for growth in the US with its diversified manufacturing base (6 FDA approved facilities including 2 in the US), pipeline of ~57 ANDAs (~67 ANDAs approved) and front-end presence.
ALKEM’s US business targets 12-15 filing and above 10 launches each year
International business (~21% of FY19 sales) with focus on certain markets Australia, Chile, some European countries, Kazakhstan and East Africa should aid growth in long-term
ALKEM’s investments in biosimilars (facility under construction in Pune) with aim of launching biosimilars to India and emerging markets should aid medium-to-long term growth.
Strong earnings growth from growth in the domestic market, strong FCF generation and global growth make Alkem an interesting stock to consider at this point.
Disclaimer: The above report is compiled from information available on public platforms. inChat team advises users to check with certified experts before taking any investment decisions.
Found this insight useful?
Please share with your friends and family as well. You can also subscribe to one of our channels listed at the bottom of this page.